Thomas Alexander Hooven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Alexander Hooven has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Ratner
Department of Microbiology, New York University Grossman School of Medicine, New York, NY, USA
10 shared publications - Tara M. Randis
Pediatrics, Morsani College of Medicine, University of South Florida
7 shared publications - Hervé Tettelin
Department of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA
6 shared publications Gideon H. Hillebrand
5 shared publications- Brandon J. Kim
Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35401, USA
4 shared publications - Christina Megli
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania
4 shared publications
Latest Publications
- 19 June 2026
- Published by Springer Nature in Pediatric Research
A controlled longitudinal study clarifies the contours of pediatric long COVID
- 19 June 2026
- Published by Springer Nature in Pediatric Research
A controlled longitudinal study clarifies the contours of pediatric long COVID
- Open Access
The bacterial cell membrane acts as a dynamic heme reservoir during group B Streptococcus bloodstream infection
During bloodstream infection, most bacterial pathogens maintain homeostatic levels of heme, which serves as an essential biochemical cofactor and iron source, but becomes toxic at high intracellular concentrations. Well-characterized, surface exposed heme binding and acquisition systems exist in several blood-borne bacterial species. However, some gram-positive bacteria that invade the bloodstream do not encode surface displayed heme acquisition systems, despite showing clear evidence of heme utilization in blood. An example is Streptococcus agalactiae (group B Streptococcus; GBS), which is a major cause of infection in neonatal and immunocompromised populations. Here we show that GBS uses its cell membrane as a dynamic heme reservoir, which functions as the primary site of environmental heme capture, sensing, and transmembrane flux. Using positive and negative genetic selection screens, targeted mutagenesis, membrane fractionation, and spectroscopic heme detection and binding assays, we demonstrate that heme is partitioned into the GBS cell membrane, where it is sensed by the histidine kinase HssS and extracted for intracellular use by the CydDC transporter. Genetically disrupting the function of either HssS heme sensing or CydDC membrane heme extraction attenuates bacterial survival in human whole blood and in a mouse model of bacteremia. These results suggest that cell membrane-localized heme homeostasis is a determinant of fitness during blood survival. This work expands the current models of bacterial heme physiology and provides evidence that membrane localized, homeostatic heme reservoirs may represent an underrecognized strategy for blood-borne pathogens that lack canonical heme acquisition systems.
Open AccessThe bacterial cell membrane acts as a dynamic heme reservoir during group B Streptococcus bloodstream infection
During bloodstream infection, most bacterial pathogens maintain homeostatic levels of heme, which serves as an essential biochemical cofactor and iron source, but becomes toxic at high intracellular concentrations. Well-characterized, surface exposed heme binding and acquisition systems exist in several blood-borne bacterial species. However, some gram-positive bacteria that invade the bloodstream do not encode surface displayed heme acquisition systems, despite showing clear evidence of heme utilization in blood. An example is Streptococcus agalactiae (group B Streptococcus; GBS), which is a major cause of infection in neonatal and immunocompromised populations. Here we show that GBS uses its cell membrane as a dynamic heme reservoir, which functions as the primary site of environmental heme capture, sensing, and transmembrane flux. Using positive and negative genetic selection screens, targeted mutagenesis, membrane fractionation, and spectroscopic heme detection and binding assays, we demonstrate that heme is partitioned into the GBS cell membrane, where it is sensed by the histidine kinase HssS and extracted for intracellular use by the CydDC transporter. Genetically disrupting the function of either HssS heme sensing or CydDC membrane heme extraction attenuates bacterial survival in human whole blood and in a mouse model of bacteremia. These results suggest that cell membrane-localized heme homeostasis is a determinant of fitness during blood survival. This work expands the current models of bacterial heme physiology and provides evidence that membrane localized, homeostatic heme reservoirs may represent an underrecognized strategy for blood-borne pathogens that lack canonical heme acquisition systems.
- Open Access
- 22 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag229
Placental Pathogens Associated With Adverse Maternal and Neonatal Outcomes
Background: Bacterial infection at the maternal-fetal interface contributes to adverse pregnancy outcomes, including preterm birth, chorioamnionitis, and sepsis. Despite evolving obstetric practices that may influence microbial patterns, recommended clinical algorithms for prophylaxis and treatment rely on outdated data. Furthermore, the pathogenic organisms associated with adverse outcomes remain incompletely characterized. Methods: We conducted a retrospective study of placental cultures from a high-risk obstetric cohort from a single hospital system between 2014 and 2019 (n = 714). Placental cultures were obtained from deliveries at high risk for infection: (eg, preterm birth or suspected chorioamnionitis). Placental cultures were stratified into pathogenic and nonpathogenic. Associated clinical outcomes, histopathology, and antimicrobial susceptibility patterns were compared. Results: Pathogenic organisms were identified in 69% of cultures (492 of 714). Group B Streptococcus (n = 161; 22.5% of total isolates) and Escherichia coli (n = 53; 7.4% of total isolates) were the most common pathogens isolated; we also identified additional pathogens, including Enterococcus faecalis (n = 44), Haemophilus (n = 37), Prevotella (n = 32), and Bacteroides species (n = 23). Pathogenic cultures were correlated with significantly higher rates of composite adverse maternal (27.0% vs 17.6%; P = .006) and neonatal (78.9% vs 60.6%; P < .001) outcomes, as well as histopathologic chorioamnionitis (72.5% vs 60.9%; P = .003). Antimicrobial resistance for recommended empiric regimens ranged from 47.1% to 87.8%. Conclusions: Bacterial pathogens isolated from the placenta in high-risk pregnancies are associated with perinatal morbidity. Group B Streptococcus and E coli remain common, and E faecalis, Haemophilus spp, and anaerobes such as Prevotella may represent emerging pathogens underrecognized in contemporary obstetric practice. Placental cultures may serve as a valuable surveillance tool for informing empiric antibiotic strategies in pregnancy.
- 22 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag229
Open AccessPlacental Pathogens Associated With Adverse Maternal and Neonatal Outcomes
Background: Bacterial infection at the maternal-fetal interface contributes to adverse pregnancy outcomes, including preterm birth, chorioamnionitis, and sepsis. Despite evolving obstetric practices that may influence microbial patterns, recommended clinical algorithms for prophylaxis and treatment rely on outdated data. Furthermore, the pathogenic organisms associated with adverse outcomes remain incompletely characterized. Methods: We conducted a retrospective study of placental cultures from a high-risk obstetric cohort from a single hospital system between 2014 and 2019 (n = 714). Placental cultures were obtained from deliveries at high risk for infection: (eg, preterm birth or suspected chorioamnionitis). Placental cultures were stratified into pathogenic and nonpathogenic. Associated clinical outcomes, histopathology, and antimicrobial susceptibility patterns were compared. Results: Pathogenic organisms were identified in 69% of cultures (492 of 714). Group B Streptococcus (n = 161; 22.5% of total isolates) and Escherichia coli (n = 53; 7.4% of total isolates) were the most common pathogens isolated; we also identified additional pathogens, including Enterococcus faecalis (n = 44), Haemophilus (n = 37), Prevotella (n = 32), and Bacteroides species (n = 23). Pathogenic cultures were correlated with significantly higher rates of composite adverse maternal (27.0% vs 17.6%; P = .006) and neonatal (78.9% vs 60.6%; P < .001) outcomes, as well as histopathologic chorioamnionitis (72.5% vs 60.9%; P = .003). Antimicrobial resistance for recommended empiric regimens ranged from 47.1% to 87.8%. Conclusions: Bacterial pathogens isolated from the placenta in high-risk pregnancies are associated with perinatal morbidity. Group B Streptococcus and E coli remain common, and E faecalis, Haemophilus spp, and anaerobes such as Prevotella may represent emerging pathogens underrecognized in contemporary obstetric practice. Placental cultures may serve as a valuable surveillance tool for informing empiric antibiotic strategies in pregnancy.
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0375225
Correction for Bhavana et al., “A group B Streptococcus indexed transposon mutant library to accelerate genetic research on an important perinatal pathogen”
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0375225
Open AccessCorrection for Bhavana et al., “A group B Streptococcus indexed transposon mutant library to accelerate genetic research on an important perinatal pathogen”
- Open Access
- 19 February 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (2) , e0037625
CRISPR interference in a Streptococcus agalactiae multi-locus sequence type 17 strain
Group B Streptococcus (GBS), a common colonizer of the human genital and gastrointestinal tracts, is a leading cause of neonatal bacterial meningitis, which can lead to severe neurological complications. The hypervirulent serotype III, sequence type 17 (ST-17) strain COH1 is strongly associated with late-onset disease due to its unique set of virulence factors. However, genetic manipulation of ST-17 strains remains challenging, limiting the ability to study key pathogenic genes. In this study, we developed a CRISPR interference (CRISPRi) system utilizing an endogenous catalytically inactivated Cas9 (dCas9) in the COH1 strain, enabling targeted and tunable gene expression knockdown. We confirmed the efficacy of this system through hemolysis assays, qPCR transcriptional analysis, and in vitro infection models using human brain endothelial cells. The CRISPRi system successfully produced phenotypic knockdowns of key virulence genes, including PI-2b, srr2 , and iagA , reducing adhesion, invasion, and inflammatory responses at the blood-brain barrier (BBB). This platform enables rapid gene knockdowns for functional genomics in ST-17 GBS, enabling high-throughput screening and pathogenesis research. IMPORTANCE: Group B Streptococcus (GBS) remains the world's leading cause of neonatal meningitis. GBS-host interactions at the blood-brain barrier (BBB) are dependent on bacterial factors, including surface factors and two-component systems. Multi-locus sequence type 17 (ST-17) GBS strains are highly associated with neonatal meningitis, and these strains harbor many virulence factors for infection at the BBB. Historically, these factors have been studied using traditional knockout mutagenesis, which has been challenging in the most common ST-17 lab strain, COH1. This study utilizes CRISPR interference (CRISPRi) to generate rapid expression knockdown. This study validates a CRISPRi-enabled COH1 dCas9 strain as a versatile tool for probing GBS pathogenesis at the BBB.
- 19 February 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (2) , e0037625
Open AccessCRISPR interference in a Streptococcus agalactiae multi-locus sequence type 17 strain
Group B Streptococcus (GBS), a common colonizer of the human genital and gastrointestinal tracts, is a leading cause of neonatal bacterial meningitis, which can lead to severe neurological complications. The hypervirulent serotype III, sequence type 17 (ST-17) strain COH1 is strongly associated with late-onset disease due to its unique set of virulence factors. However, genetic manipulation of ST-17 strains remains challenging, limiting the ability to study key pathogenic genes. In this study, we developed a CRISPR interference (CRISPRi) system utilizing an endogenous catalytically inactivated Cas9 (dCas9) in the COH1 strain, enabling targeted and tunable gene expression knockdown. We confirmed the efficacy of this system through hemolysis assays, qPCR transcriptional analysis, and in vitro infection models using human brain endothelial cells. The CRISPRi system successfully produced phenotypic knockdowns of key virulence genes, including PI-2b, srr2 , and iagA , reducing adhesion, invasion, and inflammatory responses at the blood-brain barrier (BBB). This platform enables rapid gene knockdowns for functional genomics in ST-17 GBS, enabling high-throughput screening and pathogenesis research. IMPORTANCE: Group B Streptococcus (GBS) remains the world's leading cause of neonatal meningitis. GBS-host interactions at the blood-brain barrier (BBB) are dependent on bacterial factors, including surface factors and two-component systems. Multi-locus sequence type 17 (ST-17) GBS strains are highly associated with neonatal meningitis, and these strains harbor many virulence factors for infection at the BBB. Historically, these factors have been studied using traditional knockout mutagenesis, which has been challenging in the most common ST-17 lab strain, COH1. This study utilizes CRISPR interference (CRISPRi) to generate rapid expression knockdown. This study validates a CRISPRi-enabled COH1 dCas9 strain as a versatile tool for probing GBS pathogenesis at the BBB.
- 18 November 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (5) , 1656-1657
“Head sparing” fetal growth restriction is not exactly what it sounds like
- 18 November 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (5) , 1656-1657
“Head sparing” fetal growth restriction is not exactly what it sounds like
- 3 October 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (2) , 421-422
A new study provides details on COVID-19 vaccine booster efficacy among children receiving immunosuppressive medications
- 3 October 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (2) , 421-422
A new study provides details on COVID-19 vaccine booster efficacy among children receiving immunosuppressive medications
- Open Access
- 13 September 2025
- Published by Wiley in Molecular Microbiology
- Vol. 124 (5) , 449-461
A Cas12a Toolbox for Rapid and Flexible Group B Streptococcus Genomic Editing and CRISPRi
Streptococcus agalactiae (group B Streptococcus ; GBS) is a leading cause of neonatal sepsis and meningitis. Despite advances in molecular microbiology, GBS genome engineering remains laborious due to inefficient mutagenesis protocols. Here, we report a versatile and rapid Cas12a‐based toolkit for GBS genetic manipulation. We developed two shuttle plasmids—pGBSedit for genome editing and pGBScrispri for inducible CRISPR interference—derived from an Enterococcus faecium system and optimized for GBS. Using these tools, we achieved targeted gene insertions, markerless deletions, and efficient, template‐free mutagenesis via alternative end‐joining repair. Furthermore, a catalytically inactive dCas12a variant enabled inducible gene silencing, with strand‐specific targeting effects. The system demonstrated broad applicability across multiple GBS strains and minimal off‐target activity, as confirmed by whole‐genome sequencing. In benchmarking, template‐less Cas12a mutagenesis yielded sequence‐confirmed mutants in ~7 days and homology‐directed edits in ~7–14 days; aTC‐resistant colonies arose at ~10 −4 of uninduced CFU, and 27%–65% of resistant clones carried the intended homology‐directed edit depending on locus and homology arm length (e.g., ~27% markerless deletion; ~35% insertion; 65% with 1 kb arms). These workflows provide a rapid alternative to temperature‐sensitive plasmid mutagenesis protocols that typically require ≥ 4 weeks. This Cas12a‐based platform offers an efficient, flexible, and scalable approach to genetic studies in GBS, facilitating functional genomics and accelerating pathogenesis research.
- 13 September 2025
- Published by Wiley in Molecular Microbiology
- Vol. 124 (5) , 449-461
Open AccessA Cas12a Toolbox for Rapid and Flexible Group B Streptococcus Genomic Editing and CRISPRi
Streptococcus agalactiae (group B Streptococcus ; GBS) is a leading cause of neonatal sepsis and meningitis. Despite advances in molecular microbiology, GBS genome engineering remains laborious due to inefficient mutagenesis protocols. Here, we report a versatile and rapid Cas12a‐based toolkit for GBS genetic manipulation. We developed two shuttle plasmids—pGBSedit for genome editing and pGBScrispri for inducible CRISPR interference—derived from an Enterococcus faecium system and optimized for GBS. Using these tools, we achieved targeted gene insertions, markerless deletions, and efficient, template‐free mutagenesis via alternative end‐joining repair. Furthermore, a catalytically inactive dCas12a variant enabled inducible gene silencing, with strand‐specific targeting effects. The system demonstrated broad applicability across multiple GBS strains and minimal off‐target activity, as confirmed by whole‐genome sequencing. In benchmarking, template‐less Cas12a mutagenesis yielded sequence‐confirmed mutants in ~7 days and homology‐directed edits in ~7–14 days; aTC‐resistant colonies arose at ~10 −4 of uninduced CFU, and 27%–65% of resistant clones carried the intended homology‐directed edit depending on locus and homology arm length (e.g., ~27% markerless deletion; ~35% insertion; 65% with 1 kb arms). These workflows provide a rapid alternative to temperature‐sensitive plasmid mutagenesis protocols that typically require ≥ 4 weeks. This Cas12a‐based platform offers an efficient, flexible, and scalable approach to genetic studies in GBS, facilitating functional genomics and accelerating pathogenesis research.
- Open Access
CRISPR interference in a Streptococcus agalactiae Multi-locus Sequence Type 17 Strain
Group B Streptococcus (GBS), a common colonizer of the human genital and gastrointestinal tracts, is a leading cause of neonatal bacterial meningitis, which can lead to severe neurological complications. The hypervirulent serotype III, sequence type 17 (ST-17) strain COH1 is strongly associated with late-onset disease due to its unique set of virulence factors. However, genetic manipulation of ST-17 strains is notoriously challenging, limiting the ability to study key pathogenic genes. In this study, we developed a CRISPR interference (CRISPRi) system utilizing an endogenous catalytically inactivated Cas9 (dCas9) in the COH1 strain, enabling targeted and tunable gene expression knockdown. We confirmed the efficacy of this system through hemolysis assays, qPCR transcriptional analysis, and in vitro infection models using human brain endothelial cells. The CRISPRi system successfully produced phenotypic knockdowns of essential virulence genes, including pilA, srr2 , and iagA , reducing adhesion, invasion, and inflammatory responses at the blood-brain barrier. This platform enables rapid gene knockdowns for functional genomics in ST-17 GBS, enabling high-throughput screening and pathogenesis research. Importance: Group B Streptococcus (GBS) remains the world’s leading cause of neonatal meningitis. GBS-host interactions at the blood-brain barrier (BBB) are dependent on bacterial factors, including surface factors and two-component systems. Multi-locus sequence type 17 (ST-17) GBS strains are highly associated with neonatal meningitis, and these strains harbor many virulence factors for infection at the BBB. Historically, these factors have been studied using traditional knockout mutagenesis, which has proven challenging in the most common ST-17 lab strain, COH1. This study utilizes CRISPR interference (CRISPRi) to generate rapid expression knockdown. This study validates a CRISPRi-enabled COH1 dCas9 strain as a versatile tool for probing GBS pathogenesis at the BBB.
Open AccessCRISPR interference in a Streptococcus agalactiae Multi-locus Sequence Type 17 Strain
Group B Streptococcus (GBS), a common colonizer of the human genital and gastrointestinal tracts, is a leading cause of neonatal bacterial meningitis, which can lead to severe neurological complications. The hypervirulent serotype III, sequence type 17 (ST-17) strain COH1 is strongly associated with late-onset disease due to its unique set of virulence factors. However, genetic manipulation of ST-17 strains is notoriously challenging, limiting the ability to study key pathogenic genes. In this study, we developed a CRISPR interference (CRISPRi) system utilizing an endogenous catalytically inactivated Cas9 (dCas9) in the COH1 strain, enabling targeted and tunable gene expression knockdown. We confirmed the efficacy of this system through hemolysis assays, qPCR transcriptional analysis, and in vitro infection models using human brain endothelial cells. The CRISPRi system successfully produced phenotypic knockdowns of essential virulence genes, including pilA, srr2 , and iagA , reducing adhesion, invasion, and inflammatory responses at the blood-brain barrier. This platform enables rapid gene knockdowns for functional genomics in ST-17 GBS, enabling high-throughput screening and pathogenesis research. Importance: Group B Streptococcus (GBS) remains the world’s leading cause of neonatal meningitis. GBS-host interactions at the blood-brain barrier (BBB) are dependent on bacterial factors, including surface factors and two-component systems. Multi-locus sequence type 17 (ST-17) GBS strains are highly associated with neonatal meningitis, and these strains harbor many virulence factors for infection at the BBB. Historically, these factors have been studied using traditional knockout mutagenesis, which has proven challenging in the most common ST-17 lab strain, COH1. This study utilizes CRISPR interference (CRISPRi) to generate rapid expression knockdown. This study validates a CRISPRi-enabled COH1 dCas9 strain as a versatile tool for probing GBS pathogenesis at the BBB.
- Open Access
- 8 April 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (4) , e0057324
A CRISPRi library screen in group B Streptococcus identifies surface immunogenic protein (Sip) as a mediator of multiple host interactions
Group B Streptococcus (GBS; Streptococcus agalactiae ) is an important pathobiont capable of colonizing various host environments, contributing to severe perinatal infections. Surface proteins play critical roles in GBS-host interactions; however, comprehensive studies of these proteins’ functions have been limited by genetic manipulation challenges. This study leveraged a CRISPR interference (CRISPRi) library to target genes encoding surface-trafficked proteins in GBS, identifying their roles in modulating macrophage cytokine responses. Bioinformatic analysis of 654 GBS genomes revealed 66 conserved surface protein genes. Using a GBS strain expressing chromosomally integrated dCas9, we generated and validated CRISPRi strains targeting these genes. THP-1 macrophage-like cells were exposed to ethanol-killed GBS variants, and pro-inflammatory cytokines TNF-⍺ and IL-1β were measured. Notably, knockdown of the sip gene, encoding the Surface Immunogenic Protein (Sip), significantly increased IL-1β secretion, implicating Sip in caspase-1-dependent regulation. Furthermore, Δ sip mutants demonstrated impaired biofilm formation, reduced adherence to human fetal membranes, and diminished uterine persistence in a mouse colonization model. These findings suggest that Sip modulates GBS-host interactions critical for pathogenesis, underscoring its potential as a therapeutic target or vaccine component.
- 8 April 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (4) , e0057324
Open AccessA CRISPRi library screen in group B Streptococcus identifies surface immunogenic protein (Sip) as a mediator of multiple host interactions
Group B Streptococcus (GBS; Streptococcus agalactiae ) is an important pathobiont capable of colonizing various host environments, contributing to severe perinatal infections. Surface proteins play critical roles in GBS-host interactions; however, comprehensive studies of these proteins’ functions have been limited by genetic manipulation challenges. This study leveraged a CRISPR interference (CRISPRi) library to target genes encoding surface-trafficked proteins in GBS, identifying their roles in modulating macrophage cytokine responses. Bioinformatic analysis of 654 GBS genomes revealed 66 conserved surface protein genes. Using a GBS strain expressing chromosomally integrated dCas9, we generated and validated CRISPRi strains targeting these genes. THP-1 macrophage-like cells were exposed to ethanol-killed GBS variants, and pro-inflammatory cytokines TNF-⍺ and IL-1β were measured. Notably, knockdown of the sip gene, encoding the Surface Immunogenic Protein (Sip), significantly increased IL-1β secretion, implicating Sip in caspase-1-dependent regulation. Furthermore, Δ sip mutants demonstrated impaired biofilm formation, reduced adherence to human fetal membranes, and diminished uterine persistence in a mouse colonization model. These findings suggest that Sip modulates GBS-host interactions critical for pathogenesis, underscoring its potential as a therapeutic target or vaccine component.